Regarding the import of monoisopropylamine (MIPA) that is produced in or exported from China PR, the Directorate General of Trade Remedies (DGTR) has opened an anti-dumping investigation. This action comes after Alkyl Amines Chemicals Limited filed an application claiming that unfair trade practices had caused material harm to the domestic industry
The goal of the investigation, which was started in accordance with the Anti-Dumping Rules of 1995 and the Customs Tariff Act of 1975, is to ascertain whether MIPA imports from China PR are being dumping into the Indian market at prices below their normal value, harming indigenous producers.
MIPA is an essential chemical component that is employed in the production of different drug formulations and active pharmaceutical ingredients (APIs). The investigation has important ramifications for the pharmaceutical business because of its crucial role in the chemical and pharmaceutical industries.
A list of interested parties who have registered to take part in the proceedings has been made public by DGTR as part of the ongoing inquiry. Domestic producers, importers, exporters, and other pertinent parties are on the list. Key entities registered include the following: People’s Republic of China Embassy (represented as Self), Alkyl Amines Chemicals Limited (domestic industry) (represented by TPM Consultants), Anhui Haoyuan Chemical Group Co., Ltd. (exporter) (represented by Pothal & Associates), and Crystal Crop Protection Ltd. (importers/users) (represented by ASL Legal).
Non-confidential copies (NCV) of past and upcoming submissions must be sent to all registered parties by interested parties, and a copy must be marked for the DGTR. To guarantee equitable representation in the investigation, any party who is unintentionally left off the official list is urged to notify the Directorate right away.
According to Alkyl Amines Chemicals Limited, imports from China PR are severely undercutting domestic prices, resulting in losses and having a negative impact on the Indian manufacturing industry. To level the playing field and safeguard domestic production capacity, they have asked that anti-dumping duties be imposed.
Before making a final decision regarding the imposition of anti-dumping charges, the DGTR has promised to use due diligence in examining all relevant information and submissions.
It is anticipated that the investigation’s findings would have significant ramifications for both foreign exporters and domestic producers. Pharmaceutical and chemical companies that depend on MIPA imports may be affected by price corrections in the domestic market if anti-dumping penalties are implemented. However, less competition from artificially low-priced imports will benefit Indian producers.
